ArticleAnnals of gastroenterological surgery2020
Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.
Article in Annals of gastroenterological surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.Nature medicine · 2026Trial
- Article
- Tumor antigen-associated autoantibodies: generation mechanisms, roles in tumorigenesis and progression, and clinical application prospects.Frontiers in immunology · 2026Review
- Computational Approach Improves Diagnostic Performance Based on Tumor-Associated Autoantibodies in Esophageal Squamous Cell Carcinoma.Computational and structural biotechnology journal · 2026Article
- Evaluating serum extra spindle pole bodies-like 1 proteinWorld journal of hepatology · 2025Article
- Prognostic significance of six autoantibodies in esophageal squamous cell carcinoma: A prospective multi-institutional study.Annals of gastroenterological surgery · 2025Article
- Article
- Longitudinal monitoring of autoantibody dynamics in patients with early-stage non-small-cell lung cancer undergoing surgery.Open life sciences · 2025Article
- Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.British journal of cancer · 2024Observational
- Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer.Annals of gastroenterological surgery · 2024Article
- The Role of H2-Calponin Antigen in Cancer Metastasis: Presence of Autoantibodies in Liver Cancer Patients.International journal of molecular sciences · 2023Article
- Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study.Oncology letters · 2022Article
- Preoperative Low Serum Calcium Levels Predict Poor Prognosis for Patients with Esophageal Cancer.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2022Article
- Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.Surgery today · 2021Article
- The usefulness of microRNA in urine and saliva as a biomarker of gastroenterological cancer.International journal of clinical oncology · 2021Review
- Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence.Cancers · 2021Review
- Review
- Article
- Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers.Annals of gastroenterological surgery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimWe evaluated the clinicopathological and prognostic significance of serum p53 (s-p53-Abs) and serum NY-ESO-1 autoantibodies (s-NY-ESO-1-Abs) in esophageal squamous cell carcinoma (ESCC), gastric cancer and hepatocellular carcinoma (HCC). PATIENTS AND
methodsA total of 377 patients, 85 patients with ESCC, 248 patients with gastric cancer, and 44 patients with HCC were enrolled to measure s-p53-Abs and s-NY-ESO-1-Abs titers by the enzyme-linked immunosorbent assay before treatment. The clinicopathological significance and prognostic impact of the presence of autoantibodies were evaluated. Expression data based on the Cancer Genome Atlas and the prognostic impact of gene expression was also examined for discussion.
resultsThe positive rates of s-p53-Abs were 32.9% in ESCC, 15% in gastric cancer, and 4.5% in HCC. The positive rates of s-NY-ESO-1-Abs were 29.4% in ESCC, 9.7% in gastric cancer, and 13.6% in HCC. The presence of s-p53-Abs was not associated with tumor progression in these three cancer types. On the other hand, the presence of s-NY-ESO-1-Abs was significantly associated with tumor progression in ESCC and gastric cancer. The presence of s-p53-Abs and/or s-NY-ESO-1-Abs was significantly associated with poor prognosis in gastric cancer but not in ESCC nor HCC.
conclusionsThe presence of s-p53-Abs and/or s-NY-ESO-1-Abs was associated with tumor progression in ESCC and gastric cancer. These autoantibodies might have poor prognostic impacts on gastric cancer (UMIN000014530).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.